Player FM - Internet Radio Done Right
22 subscribers
Checked 1M ago
Menambahkan seven tahun yang lalu
Konten disediakan oleh Bryn Mawr Communications (BMC) and Retina Today. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Bryn Mawr Communications (BMC) and Retina Today atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !
Offline dengan aplikasi Player FM !
New Retina Radio by Eyetube
Tandai semua (belum/sudah) diputar ...
Manage series 2134816
Konten disediakan oleh Bryn Mawr Communications (BMC) and Retina Today. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Bryn Mawr Communications (BMC) and Retina Today atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
New Retina Radio is a place to hear stories about retina that are told nowhere else.
…
continue reading
191 episode
Tandai semua (belum/sudah) diputar ...
Manage series 2134816
Konten disediakan oleh Bryn Mawr Communications (BMC) and Retina Today. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Bryn Mawr Communications (BMC) and Retina Today atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
New Retina Radio is a place to hear stories about retina that are told nowhere else.
…
continue reading
191 episode
Semua episode
×N
New Retina Radio by Eyetube

1 Rates of Ocular AEs After Faricimab Injection 18:13
18:13
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai18:13
What are the real-world safety data following administration of faricimab (Vabysmo, Genentech)? Maura Di Nicola, MD, and guests Sruthi Arepalli, MD, and Barton Blackorby, MD, review data from a real-world, single-center, retrospective study of approximately 4500 injections of faricimab in over 700 patients at Wills Eye Hospital. What did the data show? And do these data effect the clinical patterns of Drs. Di Nicola, Arepalli, and Blackorby?…
N
New Retina Radio by Eyetube

1 Treating Geographic Atrophy (GA) In Your Practice 19:18
19:18
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai19:18
Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.…
N
New Retina Radio by Eyetube

1 Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy 22:07
22:07
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai22:07
Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.
N
New Retina Radio by Eyetube

1 Using OCT Angiography to Distinguish RVO and RAO 17:36
17:36
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai17:36
How can OCT angiography help retina specialists distinguish between retinal vein occlusion (RVO) and retinal artery occlusion (RAO) in patients who present without acute findings? Using real-world cases as a backdrop, Yasha Modi, MD, and Kat Talcott, MD, discuss Dr. Modi’s approach to distinguishing RVO and RAO via OCT angiography and review which specific OCT angiography findings may indicate referral to cardiology. Later in the episode, they explore the utility and limitations of OCT angiography in patients with diabetic retinopathy. This episode is supported by Zeiss Professional Education.…
N
New Retina Radio by Eyetube

1 OCT Angiography in a Real-world CSR Case 17:59
17:59
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai17:59
What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT angiography in a real-world CSR case, discuss the value of selecting OCT angiography over fluorescein angiography for patients with neovascularization, and parse which populations are not a good fit for OCT angiography. This episode is supported by Zeiss Professional Education.…
N
New Retina Radio by Eyetube

1 Switching from Aflibercept to Faricimab in Wet AMD Patients 22:00
22:00
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai22:00
Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use findings such as these to inform their practice? And are significant improvements in anatomy relevant if vision gains are unchanged?…
N
New Retina Radio by Eyetube

1 GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment? 16:50
16:50
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai16:50
What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani, MD, as they explore which patients are best suited for treatment, how best to succinctly set expectations for outcomes, and whether patients on GA therapy may also be well-suited AREDS vitamins.…
N
New Retina Radio by Eyetube

1 AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's 31:38
31:38
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai31:38
How many real-world patients with proliferative DR were concordant with the treatment directions in Protocol S? Adrienne Scott, MD, explains how a database review of real-world patients with proliferative DR revealed how few patients are concordant with the strict dosing schedule of Protocol S, and shares which baseline factors were linked to lack of concordance. And Dilraj Grewal, MD, provides an update on the relationship between retinal imaging and detection of Alzheimer disease. Just how close are we from using noninvasive retinal imaging techniques to screen for potential neurodegenerative conditions?…
N
New Retina Radio by Eyetube

1 New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk? 15:01
15:01
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai15:01
Does metformin use reduce the risk of developing AMD in non-diabetic patients? Moderator Rebecca Soares, MD, and panelists Matt Starr, MD, and Nikisha Kothari, MD, review a decade-long case control-control study assessing risk of AMD in non-diabetic patients who have been taking metformin for any reason. They ask whether the study's blindspots undercut its findings, and speculate what other questions further research could answer.…
N
New Retina Radio by Eyetube

1 AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA 20:02
20:02
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai20:02
We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study assessing the safety and efficacy ONL1204 (ONL Therapeutics) delivered prior to RRD surgery. Did injecting ONL1204, which prevents Fas activation, lead to any postsurgical differences? Alex Melamud stops by to discuss the phase 2/3 SAGA study assessing the safety and efficacy of gildeuretinol (Alkeus Pharmaceuticals), an oral agent for the treatment of geographic atrophy. Can this drug succeed where other oral options in retina have failed?…
N
New Retina Radio by Eyetube

1 AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD 25:27
25:27
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai25:27
The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there any surprises in the data? Jeremiah Brown, MD, MS, sits down with New Retina Radio to review the philosophy behind the ELEVATUM study, discuss the study’s findings, and preview the next phases of the trial. And Eric Schneider, MD, joins the program to discuss the findings of a pivotal study assessing home OCT (Scanly, Notal Vision) in wet AMD patients. Is home OCT equivalent to in-office OCT when it comes to visualization? And do expert graders agree with an AI algorithm’s assessments of patient’s pathology?…
N
New Retina Radio by Eyetube

1 AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement 31:12
31:12
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai31:12
Are retina doctors seeing more retinal pathology following infection or vaccination? Or is there nothing to see here? Rahul Khurana, MD, joins us to discuss the findings of various health care database analyses seeking to clarify whether COVID infection or vaccination were linked to retinal manifestations. Was there a clear—or even an opaque—connection between the two? And Paul Hahn, MD, PhD, sits down with us to explain how inflation, new realities of reimbursement, and step therapy directives are playing out in retina clinics in the United States. Inflation-adjusted reimbursement is declining—but can anything be done about it? And is step therapy actually saving the system any cash?…
N
New Retina Radio by Eyetube

1 GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition? 22:50
22:50
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai22:50
We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD, as he explores this question with Miguel Busquets, MD, and Esther Kim, MD. Further in the episode, they gameplan patient conversations centered around choosing a treatment, ask how heavily to weigh safety when selecting a complement inhibitor, and preview the GA pipeline.…
N
New Retina Radio by Eyetube

1 New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis Prevention 16:59
16:59
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai16:59
In this episode of the New Retina Radio Journal Club with VBS, Maura Di Nicola, MD; Sruthi Arepalli, MD, and Barton Blackorby, MD, discuss a recent study comparing endophthalmitis rates following anti-VEGF injections with pre-treatment using either 5% Povidone Iodine or 0.05% Chlorhexidine. They highlight how prefilled syringes can reduce the risk of endophthalmitis and explore the implications for clinical practice, including antiseptic protocols, patient sensitivities, and how to navigate conflicting study outcomes. Tune in for valuable insights that could influence your injection protocols.…
N
New Retina Radio by Eyetube

1 Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR 28:42
28:42
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai28:42
Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michael Klufas, MD, joined us for a discussion about another real-world study. This time, it was a retrospective multicenter outcomes analysis following multiple injections of high-dose aflibercept (Eylea HD, Regeneron) for treatment of wet AMD, DME, and DR. How did treatment-naïve patients fare compared with previously treated patients? And did treatment intervals improve? Stick with us to find out. New Retina Radio is not affiliated with the official program of Retina Society.…
N
New Retina Radio by Eyetube

1 New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO 16:15
16:15
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai16:15
What is the relationship between retinal artery occlusion (RAO) and death, stroke, or myocardial infarction? Moderator Katherine Talcott, MD, is joined by Kyle Kovacs, MD, and Phoebe Mellen, MD, to explore the latest contribution to the literature on this topic. After the break, they discuss how best to manage patients who present to the clinic with an RAO, review academic centers' model for rapidly assessing patients with RAOs, and strategize how best to perform work-ups for patients who present to the retinal clinic with an RAO weeks after reporting reduced vision.…
N
New Retina Radio by Eyetube

1 ASRS ’24: C1q Inhibition and Metformin for AMD 23:43
23:43
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai23:43
Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when patients stopped receiving treatment. And later, Dimitra Skondra, MD, fills us in on the latest research regarding potential interactions between metformin and AMD development in non-diabetic patients. Does the future of care include metformin as prophylaxis? Stick with us to find out.…
N
New Retina Radio by Eyetube

1 New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy 17:41
17:41
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai17:41
Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinical decision-making, weigh the value of anatomic improvement that doesn't result in significant improvement in vision quality, and review their comfort with switching from legacy anti-VEGF agents to next-generation therapies.…
N
New Retina Radio by Eyetube

The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it came to treating diabetic retinopathy out to 100 weeks? Margaret Chang, MD, summarized the PAVILION study’s 2-year safety and efficacy findings regarding the PDS in patients with DR but no DME. Plus, Dr. Chang offers her opinions on what it will take for retina specialists to trust the PDS now that the next-generation model has been released. Hear what she has to say in this one-on-one interview.…
N
New Retina Radio by Eyetube

1 ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings 16:16
16:16
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai16:16
Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year’s meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of continuous dosing of pegcetacoplan (Syfovre, Apellis Pharmaceuticals). What did microperimetry findings reveal about long-term dosing with C3 inhibition? Join us in this episode to find out.…
N
New Retina Radio by Eyetube

1 New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol AC 19:37
19:37
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai19:37
Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinically relevant, and explore other risk factors that may be worthy of further investigation.…
N
New Retina Radio by Eyetube

1 From Trials to the Clinic: Using a Therapy With a Novel MOA to Treat Patients With DME 29:41
29:41
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai29:41
One of the challenges associated with current anti-VEGF therapies for the management of DME is the need for frequent injections and the potential impact on adherence and vision outcomes. Join Dr. John Kitchens and Dr. Maria Berrocal as they share their experiences treating their DME patients using a therapy with a novel mechanism of action, and how those patient outcomes have influenced their extension decisions and treatment management approaches. This special episode of New Retina Radio, and its content, is supported by Genentech USA, Inc.…
N
New Retina Radio by Eyetube

1 New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic 15:15
15:15
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai15:15
What did a review of the AAO IRIS Registry reveal about the rates of retinal vein occlusion (RVO) during the COVID-19 pandemic? Moderator Katherine Talcott, MD, sits down with Phoebe Mellen, MD, and Kyle Kovacs, MD, to review the study's conclusion that RVO rates did not increase during the pandemic, discuss challenges about talking to patients seeking causality for an ocular phenomenon, and review the relative strengths and drawbacks of relying on the IRIS Registry.…
N
New Retina Radio by Eyetube

1 A Treatment With a Novel MOA for Patients With nAMD and DME: Perspectives From the Real World 34:24
34:24
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai34:24
Recent studies have proven the therapeutic viability of a different approach in treating retinal vascular diseases. Join Dr. John Kitchens, Dr. Margaret Chang, and Dr. David Chin Yee as they discuss their clinical experiences using a therapy with a novel mechanism of action in patients with nAMD and DME. And, learn how they approach managing patients with macular edema. This special episode of New Retina Radio, and its content, is supported by Genentech USA, Inc.…
N
New Retina Radio by Eyetube

1 AMD and DME Applications in the Retina Practice: Real-world Data 21:08
21:08
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai21:08
In the second episode of this 2-part series, moderator Paul Hahn, MD, PhD, and panelists Durga Borkar, MD, MMCi, and Ted Leng, MD, turn to the findings of FARETINA-AMD and FARETINA-DME, which rely on real-world outcomes as documented in the AAO IRIS Registry. What can retina specialists learn from these studies, and how might these studies' findings affect treatment decisions?…
N
New Retina Radio by Eyetube

1 ARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depression 22:55
22:55
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai22:55
Protocol AA might be complete—but analysis of its data is far from over. What did that study’s data tell us about the relationship between leakage and DR severity? Justis Ehlers, MD, breaks down what he and his team uncovered when examining ultra-widefield images from Protocol AA, and helps us understand how machine learning might be used in future retina clinics. And Lisa Faia, MD, explains what her claims database analysis uncovered about the overlap between GA diagnoses and rates of depression and anxiety. What new info do we have that can contextualize the value of GA care?…
N
New Retina Radio by Eyetube

1 New Retina Radio Journal Club with VBS: New Retina Radio Journal Club with VBS: Is Buckling Effective for RRD in Patients at Risk for PVR? 13:57
13:57
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai13:57
How do outcomes differ for RRD patients at risk of PVR following PPV alone or combined PPV/scleral buckling? Moderator David Xu, MD, hears from panelists Barton Blackorby, MD, and Prethy Rao, MD, MPH, about a recent peer-reviewed paper published in Ophthalmology Retina covering surgical outcomes of patients with RRD who were considered high risk for PVR and underwent either PPV alone or PPV/scleral buckling. After the break, the doctors discuss the specific mechanics of a PPV/scleral buckle that may lead to successful surgery and ask whether this paper helps us better understand risk factors for PVR.…
N
New Retina Radio by Eyetube

1 ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE 16:00
16:00
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai16:00
Could next-generation anti-VEGF agents such as faricimab (Vabysmo, Genentech/Roche) and high-dose aflibercept (Eylea HD, Regeneron) be dosed as infrequently as every 20 weeks without sacrificing efficacy? And even if there are data that suggest that finding, would anyone actually adopt an interval that long in wet AMD patients? Philip Storey, MD, fills us in on TENAYA and LUCERNE data that explored, in part, how many patients could theoretically reach a 20-week dosing interval with faricimab, and which baseline factors predicted whether patients were conducive to such a strategy. And Prof. Sobha Sivaprasad joins us to review findings from PULSAR. In particular, she focuses on data examining whether wet AMD patients could be dosed as long as every 24 weeks on high-dose aflibercept. This is part 1 of 2 of NRR's ARVO 2024 coverage.…
N
New Retina Radio by Eyetube

1 GA Options in Clinical Therapy, Part 2: Real-world Cases in GA 17:20
17:20
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai17:20
David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, return for the second episode in this podcast miniseries, in which they review a trio of real-world GA cases, explore what early responses to treatment look like, and ask how to address GA in the presence of wet AMD.
N
New Retina Radio by Eyetube

1 GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment Strategies 23:42
23:42
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai23:42
Join David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, as they assess which clinical and non-clinical characteristics drive their decision-making in patients with geographic atrophy (GA). After the break, Dr. Faia shares a real-world case from her clinic in which a patient who was lost to follow-up returns to consider treatment.…
Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.